TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04202861

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In vitro antibiotic combination testing (iACT)
Description: CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
Study: NCT01434888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free tafluprost 0.0015% eye drops
Description: Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free timolol 0.5% eye drops
Description: Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
Study: NCT03643081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the camera Fluobeam
Description: Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy.
Study: NCT01434888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
Description: Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
Study: NCT00383422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arzoxifene
Description: 20 mg, oral, tablet, once a day for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg, oral, tablet, once a day for 52 weeks
Study: NCT04088851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: On Metformin
Description: Oral intake of Metformin (1 g / day) for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Off Metformin
Description: No oral intake of Metformin (1 g / day) for 2 weeks
Study: NCT03242083

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: quality of life questionnaire

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: quality of life questionnaire
Study: NCT02753829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program using Kinect of Xbox
Description: Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program using paper manual
Description: Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
Study: NCT02539446

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: attentional focus
Study: NCT02753829

Intervention type: OTHER
Group type: OTHER
Intervention: Educational component
Description: It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
Study: NCT03970395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Description: The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Therapy (LTT)
Description: The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repositioning therapy
Description: It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repositioning therapy
Description: It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed.
Study: NCT03768791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is on
Study: NCT01276457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 0.25 and 0.75 mg tablets
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.25 and 0.75 mg tablets
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine very low dose (150-300 ng/mL) microemulsion
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine low dose (350-500 ng/mL) microemulsion
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Study: NCT00825383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fiber and Moderate Fiber Diets
Description: Dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fiber and Moderate Fiber Diets
Description: Dietary
Study: NCT00608530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Psychologist-Delivered
Description: Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy-Psychologist-Delivered
Description: Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
Study: NCT02089698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-flared
Description: Mini-flared Kelman tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reversed tip
Description: Reversed Kelman tip
Study: NCT00977223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant/placebo
Description: Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
Study: NCT00242606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: titrate to 200mg over 10 weeks and maintained until end of week 26

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: titrate to 2000mg/day over 22 days, maintain until the end of week 26
Study: NCT00608530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Nurse-Delivered
Description: Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy-Nurse-Delivered
Description: Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
Study: NCT03006055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells
Study: NCT03498573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tunneling surgical technique
Description: sticky bone prepared by centrifuge patient blood and mixing with xinograft
Study: NCT03046628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TcPO2
Study: NCT02946528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urgent-start peritoneal dialysis catheter
Description: Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
Study: NCT01041833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atRA
Description: atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
Study: NCT02499224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB101
Description: Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development
Study: NCT01041833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
Study: NCT03907228

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: RHT-3201
Description: PROBIOTIC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RHT-3201
Description: PROBIOTIC
Study: NCT03454542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Modified Lens Design
Description: Randomized in a daily wear, single day (6 hours or more) evaluation
Study: NCT02921503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile topical corticosteroid app
Description: app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
Study: NCT02682186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine after dilution with sodium chloride 0.9%
Description: After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted.
Study: NCT01258088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728 Ointment
Description: 5mg/cm2, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728 Ointment
Description: 5mg/cm2, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Vehicle
Description: 5mg/cm2 BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Vehicle
Description: 5mg/cm2 BID
Study: NCT03786419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
Study: NCT01998386

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel without hydrogen peroxide
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide - White Class
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide - White Class
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide - Oral-B 3D White
Description: The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
Study: NCT01363141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular AGE Diet
Description: Regular AGE Diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low AGE Diet
Description: One year reduction in dietary AGE intake.
Study: NCT04365179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1.
Study: NCT02974491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuji apple juice
Description: On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
Study: NCT03637335

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: irradiation + carboplatin
Description: 30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: irradiation + placebo
Description: 30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
Study: NCT00452608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amido pill
Description: one pill of amido/d by mouth for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatina
Description: atorvastatina 80 mg/day by mouth for 10 days
Study: NCT04144426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
Study: NCT03404180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block
Description: All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
Study: NCT00977223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aprepitant/placebo
Description: Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
Study: NCT01839981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study: NCT03404180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Sedatives
Description: Intravenous sedation using propofol or dexmedetomidine will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral femoral cutaneous nerve blocks
Description: After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve blocks
Description: After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
Study: NCT02636010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab